FindTrial
Sign In

Evaluation of expression of PDL1 and Ki67 in the biopsy sample of Breast and lung cancer patients to know the prognosis

Evaluation of PDL1 and Ki67 Expression in patients receiving chemotherapy for Breast and lung malignancy-An Observational study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/109597
Enrollment
107
Registered
2026-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

KLE JGMM MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the histopathology proven formalin fixed paraffin embedded tissue blocks of cases of Breast carcinoma and Carcinoma Lung. Formalin fixed paraffin tissue blocks of specimens which will be obtained from cases of malignancies including: Biopsy/lumpectomy/Modified radical mastectomy in cases of carcinoma breast. Biopsy/Lobectomy in cases of Carcinoma Lung.

Exclusion criteria

Exclusion criteria: Unsatisfactory fixation of tissue or preservation of paraffin blocks. Benign lesions, insitu /pre-malignant lesions.

Design outcomes

Primary

MeasureTime frame
PDL-1 POSITIVE OR NEGATIVE Ki67 positive or negative tumors based on histomorphology and gradesTimepoint: Within 2.5years—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Prajna KS

Jawaharlal Nehru Medical College,Belagavi

hemabannur2014@gmail.com7337819039

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026